Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA/BLADDR 2020 | Genomic testing in prostate cancer

Emmanuel Seront • 7 Oct 2020
PROSCA/BLADDR 2020
Genitourinary Cancer Prostate Cancer Olaparib

Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, outlines the use of genomic testing in prostate cancer as well as abnormalities seen in these patients that influence prognosis including BRCA mutated patients that can be targeted using olaparib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Emmanuel Seront

0:53
Immunotherapy in prostate cancer
Emmanuel Seront • 7 Oct 2020
1:22
Advances in non-metastatic castration-resistant prostate cancer
Emmanuel Seront • 14 Oct 2020

Related Videos

6:36
How can we reduce disparities in prostate cancer in sub-Saharan Africa?
Onyeanunam Ekeke • 22 Apr 2024
6:26
Managing rising rates of prostate cancer in Africa
Onyeanunam Ekeke • 22 Apr 2024
1:51
Management of biochemical recurrence in prostate cancer
Jason Efstathiou • 30 Apr 2024
8:12
Unmet needs in high-risk localized and advanced prostate cancer
Jason Efstathiou • 30 Apr 2024
The content of VJOncology is intended for healthcare professionals